| Literature DB >> 35954397 |
Klaus Puschel1, Andrea Rioseco1, Gabriela Soto1, Mario Palominos1, Augusto León2, Mauricio Soto1, Beti Thompson3.
Abstract
Chile has one of the highest rates of breast cancer in Latin America. Mammography rates among women, especially those of low socioeconomic status (SES), are thought to contribute to high breast cancer morbidity and mortality. A successful randomized controlled trial among women aged 50 to 70 in a low-SES primary care clinic in Chile led to a significant increase in mammography screening rates in a two-year intervention trial. This study assesses the sustainability of the intervention after ten years and identifies factors that might have been associated with a long-term effect using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework. The mammography rates among women aged 50 to 70 in the low-SES intervention clinic were compared to two populations of women aged 50 to 70 from middle-SES clinics and to national data. Qualitative data were used to answer questions of adoption, implementation, and maintenance, while quantitative data assessed the reach and effectiveness. After ten years, low-SES women at the intervention clinic maintained significantly higher mammography screening rates vs. middle-SES women at the comparison clinics (36.2% vs. 30.1% and 19.4% p < 0.0001). Women of a low SES at the intervention clinic also had significantly higher screening rates compared to women of a low SES at a national level (44.2% vs. 34.2% p < 0.0001). RE-AIM factors contributed to understanding the long-term difference in rates. Mailed contact, outreach interventions, and the integration of health promoters as part of the Community Advisory Board were important factors associated with the effects observed. This study provides information on factors that could contribute to reducing the social gap on breast cancer screening.Entities:
Keywords: Chile; Latin America; RE-AIM framework; breast cancer; low socioeconomic status; mammography
Year: 2022 PMID: 35954397 PMCID: PMC9367461 DOI: 10.3390/cancers14153734
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Characteristics of the population in the intervention and comparison clinics.
| Characteristic | Intervention Clinic | Comparison Clinics (Combined) | National Data | |
|---|---|---|---|---|
| Eligible population ( | ||||
| 2010 | 1700 | 4832 | <0.0001 | |
| 2013 | 1752 | 4841 | 1627 | <0.0001 |
| 2017 | 1781 | 4987 | <0.0001 | |
| 2020 | 1881 | 6247 | 2170 | <0.0001 |
| Education (%) | <0.0001 | |||
| ≤8 years | 48.2 | 32.3 | 29.8 | |
| 9–12 years | 47.5 b | 26.2 | 44.6 b | |
| >12 years | 4.3 | 38.1 | 25.6 | |
| Percent under poverty level by income | 15.3 | 7.8 | 10.8 | <0.0001 |
| Mortality rate by Covid-19per 100,000 (2020–2022) | 390 | 296 | 178.9 | <0.0001 |
| Potential years of life lost per 100,000 | 79.5 | 61.0 | 66.1 | <0.0001 |
a p-values obtained by comparing the intervention clinic with the comparison clinics and national data in terms of each of the characteristics assessed. The intervention clinic was used as the reference case in all comparisons. b p-value = 0.036 when comparing the intervention clinic vs. the national data at 9–12 education years
Figure 1Mammography screening rates in the intervention and comparison clinics by year.
Activities during adoption and implementation.
| Activity | Adoption/Implementation During Intervention | Adoption/Implementation Post-Intervention (2013) | ||
|---|---|---|---|---|
| Intervention | Comparison | Intervention | Comparison | |
| Brief advice | Yes | Yes | Yes | Yes |
| Mailed contact | Yes | No | Yes | No |
| MD letter | Yes | No | No | No |
| Informational brochure | Yes | No | No | No |
| Mammogram order | Yes | No | Yes | No |
| Outreach contact | Yes | No | Yes | Yes |
| Telephone contact for non-adherent women | Yes | No | Yes | Yes |
| In-home contact, if necessary | Yes | No | No | No |
| Health promoter in CAB Local social media | Yes | No | Yes | Partially |
Figure 2National and Intervention Clinic Data for Mammography Utilization in 2010 and 2017.